Business
NuLife Announces Establishment of Wound Care Subsidiary, NuLife Medical Inc.
NuLife Announces Establishment of Wound Care Subsidiary, NuLife Medical Inc..
About this update from Gulf West Security Network Inc.
[{"type":"text","content":"\nNuLife Announces Establishment of Wound Care Subsidiary, NuLife Medical Inc.\n\nNuLife Announces Establishment of Wound Care Subsidiary, NuLife Medical Inc.\n\n\nWound Care Projected to be $20 Billion Market Worldwide by 2021\n\nSAN CLEMENTE, CA--(Marketwired - August 31, 2017) - NuLife Sciences (OTCQB: NULF) through the company's wholly-owned subsidiary, NuLife BioMed, Inc., today announced it has established a wholly-owned subsidiary, NuLife Medical Inc., to focus exclusively on applying their proprietary patented technology to the treatment of chronic wounds.Wounds that resist closure or healing, such as diabetic foot ulcers, present significant risks to patients and are a substantial cost burden to the healthcare system. Preliminary application of the NuLife Technique to wound care suggests tremendous potential to help patients and provides healthcare professionals with a solution for addressing these life threatening chronic wounds. The global market for chronic and acute wound care is substantial, and growing rapidly. Estimates suggest it is expected to exceed $20 billion by 2021.\"This represents the second application of the NuLife platform,\" said John Hollister, NuLife Sciences Chief Executive Officer. \"Our new wound care subsidiary is an opportunity to help many people by addressing another life altering challenge. We are exploring ways to develop this model both within the United States and outside the United States, as major market opportunities exist in Latin America and Asia as well.\"About NuLife SciencesNuLife Sciences Inc. (OTCQB: NULF) is a biomedical company focused on medical research and technology that has the potential to address significant unmet medical needs in applications including transplantation/regenerative medicine/cell therapy/organ and tissue transplants. Through its wholly-owned subsidiary NuLife BioMed, it is currently working on advancing human organ transplant technology based upon a patent protected and unique proprietary method (\"NuLife Technique\") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. With a massive need and market for organ transplants, and over 123K candidates waiting for an organ in the U.S. alone, NuLife's versatile technique is suitable for a variety of clinical indications. The Company has completed d...